Comment on

• [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].

  Camacho A, Pérez-Camacho I, Rivero A, Natera C, García-Lázaro M, Castón JJ, Gallo M, Kindelán JM, Torre-Cisneros J. Camacho A, et al. Enferm Infecc Microbiol Clin. 2010 Apr;28(4):239-44. doi: 10.1016/j.eimc.2009.04.003. Epub 2009 Aug 3. Enferm Infecc Microbiol Clin. 2010. PMID: 19647900 Spanish.
• [Factors related to non-prescription of tuberculin skin testing in a cohort of HIV-infected people].

  Díaz A, Diez M, Bleda MJ, Aldamiz M, Camafort M, Camino X, Cepeda C, Costa A, Ferrero O, Geijo P, Iribarren JA, Moreno S, Moreno ME, Labarga P, Pinilla J, Portu J, Pulido F, Rosa C, Santamaría JM, Telenti M, Trapiella L, Trastoy M, Viciana P. Díaz A, et al. Enferm Infecc Microbiol Clin. 2010 Apr;28(4):215-21. doi: 10.1016/j.eimc.2009.06.008. Epub 2009 Aug 15. Enferm Infecc Microbiol Clin. 2010. PMID: 19683364 Spanish.
• Interferon gamma release assays: principles and practice.

  Lalvani A, Pareek M. Lalvani A, et al. Enferm Infecc Microbiol Clin. 2010 Apr;28(4):245-52. doi: 10.1016/j.eimc.2009.05.012. Epub 2009 Sep 24. Enferm Infecc Microbiol Clin. 2010. PMID: 19783328 Review.